Your prediction
Quoin Pharmaceuticals Ltd. ADR Stock
Our community identified positive and negative aspects for Quoin Pharmaceuticals Ltd. ADR stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Quoin Pharmaceuticals Ltd. ADR stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Quoin Pharmaceuticals Ltd. ADR in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Quoin Pharmaceuticals Ltd. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Quoin Pharmaceuticals Ltd. ADR | - | - | - | - | - | - | - |
| Medpace Holdings Inc | -0.230% | 0.999% | -6.437% | 44.249% | 47.015% | 135.297% | 313.304% |
| Galapagos N.V. | -0.890% | -0.295% | 0.446% | 5.965% | 2.662% | -29.504% | -72.148% |
| Ironwood Pharmaceuticals | -1.960% | 4.795% | 12.500% | -7.273% | -27.143% | -73.689% | -69.091% |
Comments
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) had its price target lowered by analysts at Maxim Group from $15.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for QNRX provided by MarketBeat
